Loading patent…
OwnerArmando da Silva Cunha Junior, Maria Elena de Lima Perez Garcia +6inventors
InventorsArmando da Silva Cunha Junior, Maria Elena de Lima Perez Garcia, Carolina Nunes da Silva, Lays Fernanda Nunes Dourado, Perla Villani Borges da Silva, Paulo Gustavo Sampaio Lacativa, Gerhard Max Gross, Iron Francisco de Paula Junior
Estimating the term…
The present description relates to methods of treatment and pharmaceutical compositions comprising a Nitric Oxide Synthase-inducer peptide, PnPP-19. Although usable for other purposes, the composition comprising PnPP-19 is useful for treating and/or preventing eye diseases related to intraocular hypertension and/or optic nerve degeneration, such as glaucoma.
A method of reducing the intraocular pressure, comprising topically administering to an eye an effective amount of PnPP-19, as shown in SEQ ID NO:
A method of treating or preventing ischemic optic neuropathy, comprising topically administering to an eye an effective amount of PnPP-19.
A pharmaceutical composition for ophthalmic administration, comprising, in a pharmaceutically effective medium, an effective amount of PnPP-19, specifically between 0.08 to 0.72% of peptide per volume, and one or more pharmaceutically acceptable excipients.
A method of treating glaucoma in a patient, comprising topically administering to an eye of a patient in need thereof, a composition formulated for ophthalmic administration comprising, in a pharmaceutically acceptable medium, an effective amount of PnPP-19 specifically between 0.08 to 0.72% of peptide per volume.
A method of treating a patient with ocular hypertension, comprising topically administering to an eye of a patient in need thereof, a composition formulated for ophthalmic administration comprising, in a pharmaceutically acceptable medium, an effective amount of PnPP-19 specifically between 0.08 to 0.72% of peptide per volume.
A method for the reduction of intraocular pressure in a patient, comprising topically administering to an eye of a patient in need thereof, an effective amount of PnPP-19 specifically between 0.08 to 0.72% of peptide per volume, formulated for ophthalmic administration comprising, in a pharmaceutically acceptable medium.
Dependencies are inferred from the claim text.